U.K.-based Renovo saw its share price soar on opening day as investors rushed to buy stock. Renovo raised about £50 million, which will go to support its programs for new therapies to prevent scarring. Its lead drug Juvista has wrapped two mid-stage clinical trials.
- here's a Telegraph report on the offering